ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board Press release Key Updates Novembro 09, 2017
ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis Press release LEIDEN, the Netherlands, July 19, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Julho 19, 2016
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. Novembro 21, 2019
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Aug. Agosto 12, 2019
ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th Press release Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th Agosto 15, 2018
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 Press release LEIDEN, The Netherlands and CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Abril 15, 2019
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Março 11, 2019
ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial Press release Key Updates Agosto 29, 2017
ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial Press release Key Updates Junho 08, 2017
ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC Press release LEIDEN, the Netherlands, June 21, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. Junho 21, 2016